Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 68, Issue 3, Pages 307-311Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2010.07.003
Keywords
Tigecycline; Acinetobacter spp.; Multidrug resistance; Nosocomial infections
Categories
Funding
- API
- Astellas
- AstraZeneca
- Bayer
- BioMerieux
- Cadence
- Cempra
- Cerexa
- Cubist
- Daiichi
- Enanta
- Forest
- GlaxoSmithKline
- Johnson & Johnson (Ortho McNeil)
- Novartis
- Optimer
- Ordway
- Pfizer
- Shionogi
- Theravance
- TREK Diagnostics
Ask authors/readers for more resources
A total of 5127 Acinetobacter spp. were collected from 140 hospitals in 32 countries in North America (17.1%), Europe (22.9%), Latin America (25.2%), and the Asia-Pacific (APAC) region (34.8%). Tigecycline MIC distributions were bimodal against isolates from North America and APAC region, while a unimodal pattern was noted for strains from Latin America. A variable MIC distribution was noted in Europe. Only tigecycline (MIC50/90, 0.5/2 mu g/mL) and polymyxin B (MIC50/90, 0.5/1 mu g/mL; 98.6% susceptible) exhibited high activity against Acinetobacter spp. Overall, tigecycline inhibited at least 90.0% of Acinetobacter spp. isolates from all countries evaluated at <= 2 mu g/mL, as well as 95.0% of those displaying multidrug resistance. Other tested agents showed limited activity and a significant (P < 0.001) trend toward decreased susceptibility during the study period. (C) 2010 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available